Inclusive of all taxes
Levocetirizine, Montelukast & Ambroxol Hydrochloride (Sustained Release) Tablets are a specially formulated pharmaceutical combination designed for the effective management and treatment of respiratory disorders. This sustained-release tablet combines an antihistamine (Levocetirizine), a leukotriene receptor antagonist (Montelukast), and a mucolytic agent (Ambroxol Hydrochloride) to provide a comprehensive therapeutic approach targeting symptoms such as allergy-induced inflammation, bronchoconstriction, and mucus buildup in the respiratory tract. Manufactured under stringent WHO-GMP certified conditions, these tablets ensure consistent, precise dosing with a sustained release profile to maintain therapeutic plasma concentration over an extended period, enhancing patient compliance and clinical outcomes. Packaged in export-quality blister or strip packs, this formulation meets international pharmacopoeial standards (IP/USP), making it ideal for regulated and semi-regulated pharmaceutical markets globally. Its formulation is well-suited for hospital, retail, and institutional pharmaceutical supply chains requiring high-quality, reliable respiratory medications.
Key Features
| Features | Description |
|---|---|
| Active Ingredients | Levocetirizine, Montelukast, Ambroxol Hydrochloride |
| Formulation Type | Sustained Release Tablets |
| Therapeutic Use | Management of Respiratory Conditions including Allergies, Asthma, and Bronchitis |
| Manufacturing Standards | WHO-GMP Certified Facilities |
| Packaging | Export-Grade Blister or Strip Packs |
| Compliance | IP/USP Pharmacopoeial Standards |
| Shelf Life | As per Regulatory Standards |
| Dosage Accuracy | Consistent and Controlled Release |
| Market Suitability | Regulated and Semi-Regulated International Markets |
| Manufacturer | IndiGlobal Exports |
| Attributes | Description |
|---|---|
| Category | Respiratory |
| Drug Form | Tablet |
| Release Profile | Sustained Release |
| Packaging Type | Blister / Strip Packs |
| Compliance Standards | IP/USP, WHO-GMP |
| Intended Use | Treatment of respiratory allergies, asthma, bronchitis |
| Storage Conditions | Store in a cool, dry place away from direct sunlight |
| Shelf Life | According to regulatory requirements; typically 2 years |
| Dosage Form Appearance | Tablet suitable for oral administration |
| Manufacturer | IndiGlobal Exports |
*Disclaimer: The above description has been AI-generated and has not been audited or verified for accuracy. It is recommended to verify product details independently before making any purchasing decisions.
The sustained release formulation ensures a controlled and prolonged release of Levocetirizine, Montelukast, and Ambroxol Hydrochloride, maintaining consistent therapeutic levels over time and reducing the frequency of dosing, thereby improving patient compliance.
Yes, the tablets are manufactured under WHO-GMP standards and comply with IP/USP pharmacopoeial quality benchmarks, making them suitable for export to regulated and semi-regulated international pharmaceutical markets.
This combination targets multiple pathways in respiratory conditions: Levocetirizine acts as an antihistamine to reduce allergic symptoms, Montelukast blocks leukotriene receptors to prevent bronchoconstriction, and Ambroxol Hydrochloride acts as a mucolytic to thin mucus, collectively offering comprehensive relief.
The product is supplied in export-grade blister or strip packs that provide protection against moisture and contamination, ensuring the tablets' stability and integrity during transport and storage.
Yes, the formulation is designed to meet the needs of hospitals, retail pharmacies, and institutional suppliers requiring quality-assured respiratory therapy tablets.
Brand: indiglobal exports
Country Of Origin: India
Levocetirizine, Montelukast & Ambroxol Hydrochloride (Sustained Release) Tablets is a pharmaceutical product indicated for respiratory treatment. This formulation is manufactured with export-quality standards to ensure therapeutic efficacy, consistent dosage, and compliance with international healthcare regulations.
Features:Levocetirizine, Montelukast & Ambroxol Hydrochloride (Sustained Release) Tablets is developed for the effective management of respiratory conditions, offering reliable performance backed by stringent pharmaceutical standards. Each batch is carefully produced and tested to ensure consistency, safety, and compliance with global export norms.
This formulation supports the clinical treatment and ongoing care of patients with respiratory indications. Commonly prescribed in hospital and retail pharmacy settings, it ensures measurable therapeutic benefit.
Crafted in state-of-the-art facilities, this tablet formulation ensures accuracy in dosing and ease of administration. It is typically available in secure blister or strip packs suitable for bulk export or institutional supply.
The product is manufactured in facilities adhering to WHO-GMP standards and complies with pharmacopoeial quality benchmarks (IP/USP). Ideal for regulated and semi-regulated markets seeking quality-assured medications.
Inclusive of all taxes
You Save: 0
Panchkula , India
Service Provider , Professional Services, Exporter, Wholesaler
GST- 06eogps3248l1zf
Stay informed with the latest market trends, quality guides, and industry analysis
